Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.1

My Therapy App Thumbnail

The materials on this page are for you to review. If you would like to share them with your patients who have been prescribed Xolair, please direct them to the patient page, where they can view the resources themselves using this link: public/xolair-csu/patient-resources

 

 

Novartis have funded an exclusive Xolair module of the highly-rated MyTherapy app to help your patients set reminders for injections and complete PRO measures digitally.

How could you and your patients benefit from the MyTherapy app?

  • Enables patients to set injection reminders
  • Allows patients access to complete UAS7, UCT, and DLQI PRO measures via the app, with reminders
  • Contains a downloadable PDF record of PRO scoring and injections that can be shared back with the clinical team

It is free for Xolair patients but must be accessed by a unique link, either via the QR code or using the URL: www.xolair.app/418627

You can help patients to access the download link and more instructional information via the Xolair patient resources webpage, intended for patients, by sharing this URL: public/xolair-csu/patient-resources

To share with dermatology, allergy or clinical immunology colleagues also managing CSU patients, you can send them to this webpage or email them the e-flyer below:

 

MyTherapy Flyer thumbnail

MY THERAPY FLYER

Download

 

*Post hoc analysis of Phase III studies,2 omalizumab 300 mg significantly improved total DLQI scores vs placebo; – ASTERIA I: mean decrease from baseline to Week 12 of -10.3 vs -6.1 (p<0.0001), – ASTERIA II: -10.2 vs -6.1 (p=0.0004), – GLACIAL: -9.7 vs -5.1 (p<0.0001).
Novartis’ involvement in the development of the MyTherapy app content is limited to the Xolair content only, and not any other aspects of the app.

CSU, chronic spontaneous urticaria; DLQI, Dermatology Life Quality Index; UAS7, urticaria activity score (seven days); UCT, urticaria control test; PRO, patient reported outcome.

References

  1. Xolair® (omalizumab) 150 mg Summary of Product Characteristics.
  2. Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.
Rate this content: 
No votes yet
UK | April 2022 | 164038
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]